RT Journal Article
SR Electronic
T1 Rapid Biphasic Decay of Intact and Defective HIV DNA Reservoir During Acute Treated HIV Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.27.24304867
DO 10.1101/2024.03.27.24304867
A1 Barbehenn, Alton
A1 Shi, Lei
A1 Shao, Junzhe
A1 Hoh, Rebecca
A1 Hartig, Heather M.
A1 Pae, Vivian
A1 Sarvadhavabhatla, Sannidhi
A1 Donaire, Sophia
A1 Sheikhzadeh, Caroline
A1 Milush, Jeffrey
A1 Laird, Gregory M.
A1 Mathias, Mignot
A1 Ritter, Kristen
A1 Peluso, Michael
A1 Martin, Jeffrey
A1 Hecht, Frederick
A1 Pilcher, Christopher
A1 Cohen, Stephanie E.
A1 Buchbinder, Susan
A1 Havlir, Diane
A1 Gandhi, Monica
A1 Henrich, Timothy J.
A1 Hatano, Hiroyu
A1 Wang, Jingshen
A1 Deeks, Steven G.
A1 Lee, Sulggi A.
YR 2024
UL http://medrxiv.org/content/early/2024/03/28/2024.03.27.24304867.abstract
AB Antiretroviral therapy (ART) is not a cure. Upon ART cessation, virus rapidly rebounds from latently-infected cells (“the HIV reservoir”). The reservoir is largely stabilized at the time of ART initiation and then decays slowly. Here, leveraging >500 longitudinal samples from 67 people with HIV (PWH) treated during acute infection, we developed a novel mathematical model to predict reservoir decay using the intact proviral DNA assay (IPDA) from peripheral CD4+ T cells. Nonlinear generalized additive models adjusted for initial CD4+ T count, pre-ART viral load, and timing of ART initiation demonstrated rapid biphasic decay of intact DNA (week 0-5: t1/2 ∼0.71 months; week 5-24: t1/2 ∼3.9 months) that extended out to 1 year of ART, with similar trends for defective DNA. Predicted reservoir decay were faster for participants individuals with earlier timing of ART initiation, higher initial CD4+ T cell count, and lower pre-ART viral load. These estimates are ∼5-fold faster than prior reservoir decay estimates among chronic-treated PWH. Thus, these data add to our limited understanding of host viral control at the earliest stages of HIV reservoir stabilization, potentially informing future HIV cure efforts aimed at diverse, global population of PWH initiating ART at varying stages of disease.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02656511Funding StatementThe funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided written informed consent, and the institutional review board of University of California, San Fransisco approved the research.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.